March 23 | 2020 2cureX provides update regarding the COVID-19 impact on ongoing clinical programs Read more
March 23 | 2020 2cureX provides update regarding the COVID-19 impact on ongoing clinical programs Read more
March 6 | 2020 2cureX is accelerating the commercialization of IndiTreat® by signing two distributor agreements to prepare for launch in second half of 2020 Read more
March 6 | 2020 2cureX ökar takten i kommersialiseringen av IndiTreat® – tecknar två nya distributörsavtal inför lansering andra halvan av 2020 Read more
January 6 | 2020 2cureX continues its IP expansion by securing a patent on its IndiTreat test in Australia Read more
January 6 | 2020 2cureX fortsätter sin IP-expansion genom att säkra ett patent på sitt IndiTreat-test i Australien Read more
December 13 | 2019 2cureX presenterar framsteg i analysutveckling för IndiTreat® i immuno-onkologi vid ESMO Immuno-Oncology Congress i Genève 11-14 december 2019. Read more
December 13 | 2019 2cureX presented progression in the IndiTreat® immuno-oncology assay development at the ESMO Immuno-Oncology Congress in Geneva 11-14 Dec. 2019. Read more
November 22 | 2019 CORRECTION: 2cureX publishes interim report for the third quarter of 2019 Read more
November 22 | 2019 RÄTTELSE: 2cureX offentliggör delårsrapport för det tredje kvartalet 2019 Read more
October 15 | 2019 2cureX continues its IP expansion by securing a patent on Its IndiTreat test in Hong Kong Read more
October 15 | 2019 2cureX fortsätter sin IP-expansion genom säkrande av patent på sitt IndiTreat-test i Hong Kong Read more
October 8 | 2019 2cureX has made an agreement with one of the largest private cancer hospitals in the Nordic countries Read more